Posted by Michael Wonder on 26 Aug 2019
Developing real-world data and evidence to support regulatory decision-making
26 August 2019 - On 3 October, the FDA and the Duke-Margolis Center for Health Policy will hold a conference, Developing Real-World Data and Evidence to Support Regulatory Decision-Making.
The conference is funded through a cooperative agreement between the FDA and Duke-Margolis and will bring together experts to discuss the role of RWD and RWE in the regulatory decision-making setting.
The conference will examine issues addressed in the Framework for FDA’s Real-World Evidence Program, a 2018 FDA framework that outlines how the agency may use RWD and RWE to make regulatory decisions related to the effectiveness of marketed drug products.
